Since its establishment in 1992 the Colorado SPORE Tissue Bank and Biomarkers Core Laboratory(TBBC) has consistently aimed to 1. provide well characterized tissues and products derived from thosetissues to SPORE investigators, 2. assess status of submitted specimens by histological,immunohistochemical and fluorescence in situ hybridization, 3. link specimens to clinical data includingoutcomes in rigid compliance with standards for maintenance of patient confidentiality and informedconsent. The development of targeted treatments has engendered an urgent need to know the status ofthe targeted pathway, the most striking examples of which are tyrosine kinase receptor and arachidonicacid pathways. RNA, DMA and protein biomarker status can efficiently be analyzed using core equipmentand standardized methods in a single core laboratory. The Core will accordingly perform standardizedmolecular tests including quantitative RT-PCR and mutational analysis on extracts of tissue specimensobtained in support of individual SPORE research projects. Data from this testing is centrally tracked anddistributed to SPORE clinical and basic science investigators who may then incorporate these data intohypothesis generation and testing. The expanded role of the Core in biomarker testing has prompted aname change for the core to Tissue Bank and Biomarkers Core Laboratory. The Core provides specimensand testing results for invasive tumors and is the central biorepository for unique and actively accruing earlydetection and chemoprevention trials for both the Colorado SPORE and the national SPORE program,collecting data and specimens from high risk patients without carcinoma at the time of enrollment. TheCore is a unique source of biological materials that are used to investigate molecular changes thataccompany and may predict invasive tumor. Specific services provided by the Core include consenting andenrollment of patients into tissue collection trials, preparation of kits for efficient sample collection andstorage, sample procurement including but not limited to retrieval of tissue from operating andbronchoscopy suites, barcoding, accessioning and proper storage of SPORE specimens, histologicalsectioning and diagnosis of SPORE tissue samples, immunohistochemistry, and fluorescence in situhybridization (FISH). In addition, specimens are prepared for RT-PCR, mutational analysis andoligonucleotide microarray studies required in the SPORE projects. Finally, specimens and data, includingimages (see Bronchial Map Project) are tracked through the central SPORE computer system and areavailable to SPORE investigators for outcome and clinicoepidemiological correlations.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
2P50CA058187-14
Application #
7448827
Study Section
Special Emphasis Panel (ZCA1-GRB-I (J1))
Project Start
2008-05-01
Project End
2013-04-30
Budget Start
2008-05-01
Budget End
2009-04-30
Support Year
14
Fiscal Year
2008
Total Cost
$220,156
Indirect Cost
Name
University of Colorado Denver
Department
Type
DUNS #
041096314
City
Aurora
State
CO
Country
United States
Zip Code
80045
McDaniel, Nellie K; Cummings, Christopher T; Iida, Mari et al. (2018) MERTK Mediates Intrinsic and Adaptive Resistance to AXL-targeting Agents. Mol Cancer Ther 17:2297-2308
Ghosh, Moumita; Miller, York E; Vandivier, R William et al. (2018) Reply to Sohal: Airway Basal Cell Reprogramming and Epithelial-Mesenchymal Transition: A Potential Key to Understanding Early Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med 197:1645-1646
Ghosh, Moumita; Miller, York E; Nakachi, Ichiro et al. (2018) Exhaustion of Airway Basal Progenitor Cells in Early and Established Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med 197:885-896
Farago, Anna F; Taylor, Martin S; Doebele, Robert C et al. (2018) Clinicopathologic Features of Non-Small-Cell Lung Cancer Harboring an NTRK Gene Fusion. JCO Precis Oncol 2018:
He, Yayi; Liu, Sangtian; Mattei, Jane et al. (2018) The combination of anti-KIR monoclonal antibodies with anti-PD-1/PD-L1 monoclonal antibodies could be a critical breakthrough in overcoming tumor immune escape in NSCLC. Drug Des Devel Ther 12:981-986
Genova, Carlo; Socinski, Mark A; Hozak, Rebecca R et al. (2018) EGFR Gene Copy Number by FISH May Predict Outcome of Necitumumab in Squamous Lung Carcinomas: Analysis from the SQUIRE Study. J Thorac Oncol 13:228-236
Merrick, Daniel T; Edwards, Michael G; Franklin, Wilbur A et al. (2018) Altered Cell-Cycle Control, Inflammation, and Adhesion in High-Risk Persistent Bronchial Dysplasia. Cancer Res 78:4971-4983
Li, Howard Y; McSharry, Maria; Walker, Deandra et al. (2018) Targeted overexpression of prostacyclin synthase inhibits lung tumor progression by recruiting CD4+ T lymphocytes in tumors that express MHC class II. Oncoimmunology 7:e1423182
Ravichandran, Kameswaran; Holditch, Sara; Brown, Carolyn N et al. (2018) IL-33 deficiency slows cancer growth but does not protect against cisplatin-induced AKI in mice with cancer. Am J Physiol Renal Physiol 314:F356-F366
Hilberg, Frank; Tontsch-Grunt, Ulrike; Baum, Anke et al. (2018) Triple Angiokinase Inhibitor Nintedanib Directly Inhibits Tumor Cell Growth and Induces Tumor Shrinkage via Blocking Oncogenic Receptor Tyrosine Kinases. J Pharmacol Exp Ther 364:494-503

Showing the most recent 10 out of 435 publications